Publications
TGFß in GI Fibrosis
Ray, K. Digestive Disease Week 2025. Nat Rev Gastroenterol Hepatol (2025). https://doi.org/10.1038/s41575-025-01083-7
Rieder, F. A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of AGMB-129 in Patients with Fibrostenotic Crohn’s Disease: Interim Results from the STENOVA Trial. DDW Clinical Late Breaking Session 5275 at Digestive Disease Week 2025, San Diego, CA, USA; May 3–6, 2025.
Sáez-Borderías, A., T Van Kaem, J Alberti, P J Stiers, C Sabadie, R Van Heeswijk, T Senso, B Pampín, R Bosser, P Wiesel. AGMB-129, an investigational ALK5 inhibitor for the treatment of Fibrostenosing Crohn’s Disease (FSCD), shows gastrointestinal (GI) restricted pharmacokinetics (PK) and a favorable safety profile in healthy subjects, Journal of Crohn’s and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i796, https://doi.org/10.1093/ecco-jcc/jjae190.0508
Sáez-Borderías, A., T Van Kaem, J Alberti, P J Stiers, C Sabadie, R Van Heeswijk, T Senso, B Pampín, R Bosser, P Wiesel. AGMB-129, an investigational ALK5 inhibitor for the treatment of Fibrostenosing Crohn’s Disease (FSCD), shows gastrointestinal (GI) restricted pharmacokinetics (PK) and a favorable safety profile in healthy subjects. ECCO 2025 Poster Presentation , Berlin, Germany; February 19-22, 2025.
Kong, L. et al. Single-cell and spatial transcriptomics of stricturing Crohn’s disease highlights a fibrosis-associated network, Nature Genetics, 57, Pages 1742-1753, 2025. https://doi.org/10.1038/s41588-025-02225-y
Rieder, F. et al. Fibrosis: cross-organ biology and pathways to development of innovative drugs, Nature Reviews Drug Discovery, 24, Pages 543-569, 2025. https://doi.org/10.1038/s41573-025-01158-9
Bettenworth, D. et al. A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice, Nature Reviews Gastroenterology & Hepatology, 21, Pages 572–584, 2024. https://doi.org/10.1038/s41575-024-00935-y
Chauhan, G.; Massey, W.J.; Veisman, I.; Rieder, F, Anti-fibrotics in inflammatory bowel diseases: Challenges and successes, Advances in Pharmacology, 101, Pages 85-106, 2024.
TGFß in IPF
TGFß in Liver Fibrosis
Toxicity of systemic TGFß blockade
HGF/ MET Pathway Overview
HGF/ MET Pathway in Disease
Disclaimer
The publications reflect historical data. Agomab does not warrant that these data are accurate, complete or up-to-date as of the date you access such publications. All Agomab product candidates mentioned in these publications are investigational in nature and have not been approved yet by any regulatory authority. Their efficacy and safety have not been established. The content of these publications is not intended for patients. Patients should always consult with a doctor or other healthcare professionals for medical advice or information about diagnosis and treatment.